chronic kidney disease
Conditions
Interventions
Experimental Group:Dapagliflozin 10mg qd
Control group:Blank control
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Chronic kidney disease (abnormal renal structure or function: proteinuria, abnormal urinary sediment, renal tubule-related lesions, abnormal histological examination and abnormal imaging examination) for more than 3 months; 2. Patients diagnosed with chronic kidney disease (including nephrotic syndrome or nephritic syndrome) in the Department of Nephrology of our hospital; 2. Aged from 18 to 80 years old; 3. Take dapagliflozin regularly; 4. 24-hour urinary protein =150mg/24h; 5. Use stable doses of an angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) for longer than 1 week.
Exclusion criteria
Exclusion criteria: 1. Severe liver dysfunction; 2. Severe renal impairment, eGFR=15 mL/min/1.73m2; 3. Urinary tract infection; 4. Osteoporosis; Type 5.1 or type 2 diabetes mellitus, polycystic kidney disease, lupus nephritis, or ANCA-associated vasculitis; 6. The presence of events that may affect the follow-up, such as the presence of malignant tumors, drug or alcohol abuse, severe respiratory diseases; 7. Exclude patients with severe mental disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma drug concentrations; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary Drug concentration; | — |
Countries
China
Contacts
Public ContactHui Zhong
West China Hospital of Sichuan University
Outcome results
None listed